Skip to content
The Twenty Minute VCThe Twenty Minute VC

Mark Goldberg: Why Politics is Rife & Decision-Making is Broken in Large VCs | E1219

Mark Goldberg is a Managing Partner and Co-Founder at Chemistry, a $350M fund announced just yesterday with the mission to lead the best seed and Series A rounds. Before Chemistry, Mark was a Partner at Index Ventures, where he led early stage investments in Plaid, Bridge, Pilot, Anrok and Persona. Prior to Index Ventures, Mark was one of the first business hires at Dropbox. ----------------------------------------------- Timestamps: (00:00) Intro (01:14) Why Did Mark Start Chemistry in a Crowded VC Market? (02:21) Fund Size & Its Impact on Founder Alignment (03:03) Multi-Stage Firms (10:37) Is Venture Now a Low-Margin, Commoditized Industry? (15:58) Concerns Over Growing Seed Round Sizes (17:50) Competitive vs. Non-Competitive Markets (19:37) Why Does Execution Often Fail Post-Product Market Fit? (23:45) What Was Mark’s Strategy for Organizing the Fundraise (29:37) What Was the Most Common Reason Investors Said No? (31:12) Best & Worst LP Meetings (33:46) Most Recent Disagreement as a Parnership (38:18) What Happens to Companies with Overinflated Valuations by Multi-Stage Funds? (40:27) Investing in AI Today (44:22) Meeting an Amazing Founder in a Bad Market (48:47) What Mark Compromises First: Check Size or Ownership (50:57) Quick-Fire Round ----------------------------------------------- In Today’s Episode with Mark Goldberg We Discuss: 1. The Truth About Multi-Stage Firms: Why are portfolio services there to help the investing partners and not the founders? What are the most broken elements within a multi-stage firm? How does decision-making break down in large partnerships? When is the right time to work with multi-stage firms? When is not? 2. From Boutique High Margins to Commoditised Low Margins: With the immense amount of cash that has entered VC, will returns simply get worse? Who will be the winners in the next 10 years of venture? Who will be the losers? What can they do today to change this? What element of the future of venture are not enough people spending time on? 3. Lessons from Leading Unicorn Company Rounds: What happens to all the unicorns with insanely high prices they cannot grow into? What has been Mark’s biggest hit? What did he learn? What has been his biggest miss? How did that change his go-forward approach? Does Mark agree that 90% of VC do not add value? ----------------------------------------------- Subscribe on Spotify: https://open.spotify.com/show/3j2KMcZTtgTNBKwtZBMHvl?si=85bc9196860e4466 Subscribe on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-twenty-minute-vc-20vc-venture-capital-startup/id958230465 Follow Harry Stebbings on Twitter: https://twitter.com/HarryStebbings Follow Mark Goldberg on Twitter: https://twitter.com/Mark_Goldberg_ Follow 20VC on Instagram: https://www.instagram.com/20vchq Follow 20VC on TikTok: https://www.tiktok.com/@20vc_tok Visit our Website: https://www.20vc.com Subscribe to our Newsletter: https://www.thetwentyminutevc.com/contact ----------------------------------------------- #20vc #harrystebbings #markgoldberg #chemistry #venturecapital #fundraising #multistagefirms

Mark GoldbergguestHarry Stebbingshost
Oct 24, 202456mWatch on YouTube ↗

At a glance

WHAT IT’S REALLY ABOUT

Inside Chemistry: Fixing Broken VC Decisions And Founder Misalignment

  1. Mark Goldberg, co-founder of new firm Chemistry and former Index Ventures partner, explains why he believes large multi-stage VC platforms have become bureaucratic, politicized, and misaligned with founders. He argues for a return to small, focused, boutique-style partnerships where experienced partners spend most of their time on early-stage founders rather than managing internal organizations. Chemistry’s model centers on a concentrated seed/Series A strategy, light reserves, single-partner decision authority, and deep founder relationships, explicitly rejecting consensus ICs and heavy platform-service structures. The conversation also covers fundraising from LPs, portfolio construction, AI and fintech investing, and why brutal feedback, independent thinking, and founder quality matter more than brand names or market fashion.

IDEAS WORTH REMEMBERING

5 ideas

Small, focused funds can realign incentives between GPs and founders.

Goldberg argues that as funds grow large and multi-stage, senior partners spend more time on internal management and politics than on new deals and founders, so Chemistry was intentionally designed as a $350M, early-stage-focused boutique partnership.

Portfolio services at big platforms often primarily serve the VC, not the founder.

He contends that talent, BD, and other platform teams evolved from a genuine innovation into a scaling crutch that justifies larger AUM, while often disintermediating the direct founder–partner relationship that actually matters most.

Consensus early-stage decision-making produces consensus portfolios.

Chemistry uses a single-trigger model where any GP can greenlight a deal, based on the belief that legendary outliers usually start as non-consensus bets that would die in a committee-driven IC process.

Light, selective reserves may be healthier than automatic pro rata.

Instead of “peanut buttering” follow-on capital across all existing companies, Chemistry runs a light-reserve model that doubles down only where conviction remains very high, which Goldberg sees as better for both LPs and founders.

Founder quality and relationship trump market fashion or category risk.

Goldberg repeatedly insists that great founders can iterate into great markets, even in “bad” categories like lending, and that the most valuable VC work is being present for “magic moments” (e.g., co-founder issues), not operational minutiae.

WORDS WORTH SAVING

5 quotes

One of the dirty secrets of multi-stage investing is that portfolio services teams are not for founders, they're for the VCs.

Mark Goldberg

The biggest mistake is when you try to make consensus decisions at the early stage; I think you end up with consensus funds.

Mark Goldberg

The world doesn't need another venture fund. It needs a new venture fund.

Mark Goldberg

Do no harm should be beating 80% of the industry.

Mark Goldberg

Every VC should have to fundraise just to be table stakes as a VC.

Mark Goldberg

Why multi-stage VC firms become bureaucratic and misaligned with foundersChemistry’s fund strategy: size, stage focus, reserves, and decision-makingValue (and limits) of platforms, brands, and portfolio services in VCFounder selection: first-time vs serial, execution, and resilienceFundraising from LPs and the shift from boutique to industrialized ventureValuations, round sizes, and portfolio construction in today’s marketApproaches to AI, fintech, and “unloved” or over-crowded market categories

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome